Cargando…

A Modified R-Type Bacteriocin Specifically Targeting Clostridium difficile Prevents Colonization of Mice without Affecting Gut Microbiota Diversity

Clostridium difficile is a leading cause of nosocomial infections worldwide and has become an urgent public health threat requiring immediate attention. Epidemic lineages of the BI/NAP1/027 strain type have emerged and spread through health care systems across the globe over the past decade. Limitin...

Descripción completa

Detalles Bibliográficos
Autores principales: Gebhart, Dana, Lok, Stephen, Clare, Simon, Tomas, Myreen, Stares, Mark, Scholl, Dean, Donskey, Curtis J., Lawley, Trevor D., Govoni, Gregory R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Microbiology 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453579/
https://www.ncbi.nlm.nih.gov/pubmed/25805733
http://dx.doi.org/10.1128/mBio.02368-14
_version_ 1782374477517029376
author Gebhart, Dana
Lok, Stephen
Clare, Simon
Tomas, Myreen
Stares, Mark
Scholl, Dean
Donskey, Curtis J.
Lawley, Trevor D.
Govoni, Gregory R.
author_facet Gebhart, Dana
Lok, Stephen
Clare, Simon
Tomas, Myreen
Stares, Mark
Scholl, Dean
Donskey, Curtis J.
Lawley, Trevor D.
Govoni, Gregory R.
author_sort Gebhart, Dana
collection PubMed
description Clostridium difficile is a leading cause of nosocomial infections worldwide and has become an urgent public health threat requiring immediate attention. Epidemic lineages of the BI/NAP1/027 strain type have emerged and spread through health care systems across the globe over the past decade. Limiting person-to-person transmission and eradicating C. difficile, especially the BI/NAP1/027 strain type, from health care facilities are difficult due to the abundant shedding of spores that are impervious to most interventions. Effective prophylaxis for C. difficile infection (CDI) is lacking. We have genetically modified a contractile R-type bacteriocin (“diffocin”) from C. difficile strain CD4 to kill BI/NAP1/027-type strains for this purpose. The natural receptor binding protein (RBP) responsible for diffocin targeting was replaced with a newly discovered RBP identified within a prophage of a BI/NAP1/027-type target strain by genome mining. The resulting modified diffocins (a.k.a. Avidocin-CDs), Av-CD291.1 and Av-CD291.2, were stable and killed all 16 tested BI/NAP1/027-type strains. Av-CD291.2 administered in drinking water survived passage through the mouse gastrointestinal (GI) tract, did not detectably alter the mouse gut microbiota or disrupt natural colonization resistance to C. difficile or the vancomycin-resistant Enterococcus faecium (VREF), and prevented antibiotic-induced colonization of mice inoculated with BI/NAP1/027-type spores. Given the high incidence and virulence of the pathogen, preventing colonization by BI/NAP1/027-type strains and limiting their transmission could significantly reduce the occurrence of the most severe CDIs. This modified diffocin represents a prototype of an Avidocin-CD platform capable of producing targetable, precision anti-C. difficile agents that can prevent and potentially treat CDIs without disrupting protective indigenous microbiota.
format Online
Article
Text
id pubmed-4453579
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher American Society of Microbiology
record_format MEDLINE/PubMed
spelling pubmed-44535792015-06-03 A Modified R-Type Bacteriocin Specifically Targeting Clostridium difficile Prevents Colonization of Mice without Affecting Gut Microbiota Diversity Gebhart, Dana Lok, Stephen Clare, Simon Tomas, Myreen Stares, Mark Scholl, Dean Donskey, Curtis J. Lawley, Trevor D. Govoni, Gregory R. mBio Research Article Clostridium difficile is a leading cause of nosocomial infections worldwide and has become an urgent public health threat requiring immediate attention. Epidemic lineages of the BI/NAP1/027 strain type have emerged and spread through health care systems across the globe over the past decade. Limiting person-to-person transmission and eradicating C. difficile, especially the BI/NAP1/027 strain type, from health care facilities are difficult due to the abundant shedding of spores that are impervious to most interventions. Effective prophylaxis for C. difficile infection (CDI) is lacking. We have genetically modified a contractile R-type bacteriocin (“diffocin”) from C. difficile strain CD4 to kill BI/NAP1/027-type strains for this purpose. The natural receptor binding protein (RBP) responsible for diffocin targeting was replaced with a newly discovered RBP identified within a prophage of a BI/NAP1/027-type target strain by genome mining. The resulting modified diffocins (a.k.a. Avidocin-CDs), Av-CD291.1 and Av-CD291.2, were stable and killed all 16 tested BI/NAP1/027-type strains. Av-CD291.2 administered in drinking water survived passage through the mouse gastrointestinal (GI) tract, did not detectably alter the mouse gut microbiota or disrupt natural colonization resistance to C. difficile or the vancomycin-resistant Enterococcus faecium (VREF), and prevented antibiotic-induced colonization of mice inoculated with BI/NAP1/027-type spores. Given the high incidence and virulence of the pathogen, preventing colonization by BI/NAP1/027-type strains and limiting their transmission could significantly reduce the occurrence of the most severe CDIs. This modified diffocin represents a prototype of an Avidocin-CD platform capable of producing targetable, precision anti-C. difficile agents that can prevent and potentially treat CDIs without disrupting protective indigenous microbiota. American Society of Microbiology 2015-03-24 /pmc/articles/PMC4453579/ /pubmed/25805733 http://dx.doi.org/10.1128/mBio.02368-14 Text en Copyright © 2015 Gebhart et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 3.0 Unported license (http://creativecommons.org/licenses/by/3.0/) .
spellingShingle Research Article
Gebhart, Dana
Lok, Stephen
Clare, Simon
Tomas, Myreen
Stares, Mark
Scholl, Dean
Donskey, Curtis J.
Lawley, Trevor D.
Govoni, Gregory R.
A Modified R-Type Bacteriocin Specifically Targeting Clostridium difficile Prevents Colonization of Mice without Affecting Gut Microbiota Diversity
title A Modified R-Type Bacteriocin Specifically Targeting Clostridium difficile Prevents Colonization of Mice without Affecting Gut Microbiota Diversity
title_full A Modified R-Type Bacteriocin Specifically Targeting Clostridium difficile Prevents Colonization of Mice without Affecting Gut Microbiota Diversity
title_fullStr A Modified R-Type Bacteriocin Specifically Targeting Clostridium difficile Prevents Colonization of Mice without Affecting Gut Microbiota Diversity
title_full_unstemmed A Modified R-Type Bacteriocin Specifically Targeting Clostridium difficile Prevents Colonization of Mice without Affecting Gut Microbiota Diversity
title_short A Modified R-Type Bacteriocin Specifically Targeting Clostridium difficile Prevents Colonization of Mice without Affecting Gut Microbiota Diversity
title_sort modified r-type bacteriocin specifically targeting clostridium difficile prevents colonization of mice without affecting gut microbiota diversity
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453579/
https://www.ncbi.nlm.nih.gov/pubmed/25805733
http://dx.doi.org/10.1128/mBio.02368-14
work_keys_str_mv AT gebhartdana amodifiedrtypebacteriocinspecificallytargetingclostridiumdifficilepreventscolonizationofmicewithoutaffectinggutmicrobiotadiversity
AT lokstephen amodifiedrtypebacteriocinspecificallytargetingclostridiumdifficilepreventscolonizationofmicewithoutaffectinggutmicrobiotadiversity
AT claresimon amodifiedrtypebacteriocinspecificallytargetingclostridiumdifficilepreventscolonizationofmicewithoutaffectinggutmicrobiotadiversity
AT tomasmyreen amodifiedrtypebacteriocinspecificallytargetingclostridiumdifficilepreventscolonizationofmicewithoutaffectinggutmicrobiotadiversity
AT staresmark amodifiedrtypebacteriocinspecificallytargetingclostridiumdifficilepreventscolonizationofmicewithoutaffectinggutmicrobiotadiversity
AT scholldean amodifiedrtypebacteriocinspecificallytargetingclostridiumdifficilepreventscolonizationofmicewithoutaffectinggutmicrobiotadiversity
AT donskeycurtisj amodifiedrtypebacteriocinspecificallytargetingclostridiumdifficilepreventscolonizationofmicewithoutaffectinggutmicrobiotadiversity
AT lawleytrevord amodifiedrtypebacteriocinspecificallytargetingclostridiumdifficilepreventscolonizationofmicewithoutaffectinggutmicrobiotadiversity
AT govonigregoryr amodifiedrtypebacteriocinspecificallytargetingclostridiumdifficilepreventscolonizationofmicewithoutaffectinggutmicrobiotadiversity
AT gebhartdana modifiedrtypebacteriocinspecificallytargetingclostridiumdifficilepreventscolonizationofmicewithoutaffectinggutmicrobiotadiversity
AT lokstephen modifiedrtypebacteriocinspecificallytargetingclostridiumdifficilepreventscolonizationofmicewithoutaffectinggutmicrobiotadiversity
AT claresimon modifiedrtypebacteriocinspecificallytargetingclostridiumdifficilepreventscolonizationofmicewithoutaffectinggutmicrobiotadiversity
AT tomasmyreen modifiedrtypebacteriocinspecificallytargetingclostridiumdifficilepreventscolonizationofmicewithoutaffectinggutmicrobiotadiversity
AT staresmark modifiedrtypebacteriocinspecificallytargetingclostridiumdifficilepreventscolonizationofmicewithoutaffectinggutmicrobiotadiversity
AT scholldean modifiedrtypebacteriocinspecificallytargetingclostridiumdifficilepreventscolonizationofmicewithoutaffectinggutmicrobiotadiversity
AT donskeycurtisj modifiedrtypebacteriocinspecificallytargetingclostridiumdifficilepreventscolonizationofmicewithoutaffectinggutmicrobiotadiversity
AT lawleytrevord modifiedrtypebacteriocinspecificallytargetingclostridiumdifficilepreventscolonizationofmicewithoutaffectinggutmicrobiotadiversity
AT govonigregoryr modifiedrtypebacteriocinspecificallytargetingclostridiumdifficilepreventscolonizationofmicewithoutaffectinggutmicrobiotadiversity